04.30.24
Global life sciences company, Cytiva, is creating solutions to the challenges of viral vector-based gene therapies with its new ELEVECTA cell lines.
According to Emmanuel Abate, President Genomic Medicine, Cytiva: “To make gene therapy a realistic option for more patients, we need to be able to standardize its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”
Tapping into its deep expertise, the company has created three cell lines for adeno-associated virus (AAV) production. Together, the three lines comprehensively meet the distinct objectives of various therapeutic programs with the ability to transition between cell lines as needs evolve, and they can be paired with Cytiva’s established cell culture media offering:
“We now offer end-to-end solutions for viral vector manufacturing,” says Abate. “With our new cell line offering, our customers can deliver higher quality treatments and significantly improve patient access today as well as meet the increasing demand for viral vector material tomorrow.”
According to Emmanuel Abate, President Genomic Medicine, Cytiva: “To make gene therapy a realistic option for more patients, we need to be able to standardize its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”
Tapping into its deep expertise, the company has created three cell lines for adeno-associated virus (AAV) production. Together, the three lines comprehensively meet the distinct objectives of various therapeutic programs with the ability to transition between cell lines as needs evolve, and they can be paired with Cytiva’s established cell culture media offering:
- A transient cell line that provides speed and flexibility enabling researchers to easily integrate it into their existing workflow. This cell line is paired with a new cell culture medium, HyClone prime expression designed to enhance performance. Both the cell line and corresponding media will be available soon.
- A packaging cell line that eases the screening of genes of interest while enabling efficiencies across clinical stages and assets. This line is available now in selected formulations.
- A producer cell line that stably integrates all four required genes for AAV production. Production starts by simply adding an induction agent—no transfection is needed. This line is available now to be customized to each individual therapy.
“We now offer end-to-end solutions for viral vector manufacturing,” says Abate. “With our new cell line offering, our customers can deliver higher quality treatments and significantly improve patient access today as well as meet the increasing demand for viral vector material tomorrow.”
